The aim of this study was to assess the changes in the levels of the blood serum pro-and anti-inflammatory cytokines in rats with experimental bronchopneumonia and after administration of immunomodulators. Materials and Methods: Research was carried out on mature male Wistar rats (n=111), weighing 220-250g. The bronchopulmonary inflammation in the rats was modeled by administration of 0.1 ml of gum turpentine in the rats' trachea under etherization. All rats were divided into four groups: Group 1 included intact animals (n=18); Group 2 included animals having bronchopneumonia (n=19); Group 3 included animals having bronchopneumonia treated with Krezacin (n=15); Group 4 included animals having bronchopneumonia treated with Metaprot (n=16). Right after the operation and for the next 5 days, a solution of one of the test immunomodulators was injected (once a day) abdominally in the experimental animals: 25mg/kg of Krezacin or 25mg/kg of Metaprot. On Day 5 of the experiment, the animals were decapitated under anesthesia and blood samples were collected. The concentration of cytokines in the blood was determined by the flow immunofluorometry method with the device Bio-RadLaboratories (USA). Results: The administration of Krezacin in animals with bronchopneumonia, in comparison with untreated animals, was accompanied by a statistically significant increase in the levels of IL-1β (by 3.43 times), IL-2 (by 1.95 times), INF-γ (by 3.29 times), and MCP-1 (by 2.07 times) and a decrease in the levels of TNFα (by 1.85 times) and IL-6 (by 2.20 times). Administration of Krezacin increased anti-inflammatory cytokines considerably: IL-4 by 5.22 times and IL-10 by 2.41 times. Analysis of results after administration of Metaprot demonstrates an increase in the levels of IL-1β (by 2.57 times), IL-2 (by 2 times), INF-γ (by 3.21 times), and MCP-1 (by 1.98 times) and a decrease in the levels of TNFα (by 2.17 times) and IL-6 (by 2.5 times), compared to data on untreated animals. Anti-inflammatory cytokines also increased greatly: IL-4 by 5.3 times and IL-10 by 3.71 times. Conclusion: The results obtained show that investigated preparations reduce the severity and intensity of bronchopneumonia in rats. Krezacin and Metaprot demonstrate the properties of true immunomodulators, increasing protective properties of cytokines and providing the adaptive response of the body in severe bronchopulmonary pathology.